Swiss - Delayed Quote CHF

Basilea Pharmaceutica AG (BSLN.SW)

43.65
+0.20
+(0.46%)
At close: May 15 at 5:30:33 PM GMT+2
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for BSLN.SW

Recent News: BSLN.SW

View More
Strong sales for Cresemba® (isavuconazole) in Japan trigger second milestone payment from Asahi Kasei Pharma to Basilea

Strong sales for Cresemba® (isavuconazole) in Japan trigger second milestone payment from Asahi Kasei Pharma to Basilea
GlobeNewswire 21 days ago
Basilea shareholders approve all proposals of the board of directors at the annual general meeting

Basilea shareholders approve all proposals of the board of directors at the annual general meeting
GlobeNewswire 29 days ago
Basilea reports presentation of new data for fosmanogepix, isavuconazole (Cresemba®) and ceftobiprole (Zevtera®) at ESCMID Global 2025

Basilea reports presentation of new data for fosmanogepix, isavuconazole (Cresemba®) and ceftobiprole (Zevtera®) at ESCMID Global 2025
GlobeNewswire 29 days ago
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
GlobeNewswire 2 months ago
Basilea reports strong 2024 full-year results with significant increase in revenue, profit and operating cash flow

Basilea reports strong 2024 full-year results with significant increase in revenue, profit and operating cash flow
GlobeNewswire 2 months ago
Strong launch for Cresemba in Japan triggers first sales milestone payment from AKP to Basilea

Strong launch for Cresemba in Japan triggers first sales milestone payment from AKP to Basilea
GlobeNewswire 3 months ago
Strong sales growth for Cresemba and Zevtera trigger further milestone payments to Basilea

Strong sales growth for Cresemba and Zevtera trigger further milestone payments to Basilea
GlobeNewswire 3 months ago
Basilea provides portfolio update and outlook

Basilea provides portfolio update and outlook
GlobeNewswire 4 months ago
Basilea is awarded additional CARB-X funding to develop new drug candidate from a novel class of antibiotics

Basilea is awarded additional CARB-X funding to develop new drug candidate from a novel class of antibiotics
GlobeNewswire 4 months ago
Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States

Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States
GlobeNewswire 4 months ago
Basilea initiates clinical phase 3 study with antifungal fosmanogepix in candidemia and invasive candidiasis

Basilea initiates clinical phase 3 study with antifungal fosmanogepix in candidemia and invasive candidiasis
GlobeNewswire 7 months ago
View More

Related Tickers

4588.T Oncolys BioPharma Inc.
533.00
+1.33%
 
4565.T Nxera Pharma Co., Ltd.
821.00
+0.61%
 
BIOV.SW BioVersys N
34.70
0.00%
 
VSC.F 4SC AG
2.4800
0.00%
 
4587.T PeptiDream Inc.
1,766.00
-0.54%
 
PHVS Pharvaris N.V.
15.91
-1.00%
 
MDG1.DE Medigene AG
0.1335
-27.64%
 
IDIA.SW Idorsia Ltd
1.3080
+0.31%
 
9688.HK Zai Lab Limited
23.000
+3.60%
 
LVTX LAVA Therapeutics N.V.
1.2600
-0.79%